American Medical Systems Holdings (NASDAQ: AMMD) provides
medical solutions designed to restore the pelvic health of men and women. It manufactures and markets surgical products to urologists, gynecologists, and urogynecologists for erectile restoration, benign prostatic hyperplasia, male urethral stricture, urinary and fecal incontinence, menorrhagia, and pelvic organ prolapse. Boston Scientific (NYSE: BSX) and Johnson & Johnson (NYSE: JNJ) are major competitors.
The stock lost ground at the end of October, on a slightly weaker than expected third quarter report. It has risen fifteen percent since that time, however, on word of insider buying, a pair of upgrades, in-line to upside fourth quarter guidance and the replacement of the CEO by the COO.
Big 3 CEOs drive to Washington to suck up to Congress
GM and Ford ready weak pitches for taxpayer bucks
Cramer on BloggingStocks: A troika of opportunity and trouble 
